Evaluating Drug-Drug Interaction Risk Associated with Peptide Analogs Using advanced In Vitro Systems.

Autor: Nørgaard RA; Development ADME, Novo Nordisk A/S, Måløv, Denmark (R.A.N., D.K.B., C.G.-J., C.S.); Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark (E.J., T.B.S.); Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark (T.B.S.); and Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester, United Kingdom (A.G.) RNQR@novonordisk.com CXLS@novonordisk.com., Bhatt DK; Development ADME, Novo Nordisk A/S, Måløv, Denmark (R.A.N., D.K.B., C.G.-J., C.S.); Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark (E.J., T.B.S.); Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark (T.B.S.); and Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester, United Kingdom (A.G.)., Järvinen E; Development ADME, Novo Nordisk A/S, Måløv, Denmark (R.A.N., D.K.B., C.G.-J., C.S.); Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark (E.J., T.B.S.); Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark (T.B.S.); and Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester, United Kingdom (A.G.)., Stage TB; Development ADME, Novo Nordisk A/S, Måløv, Denmark (R.A.N., D.K.B., C.G.-J., C.S.); Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark (E.J., T.B.S.); Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark (T.B.S.); and Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester, United Kingdom (A.G.)., Gabel-Jensen C; Development ADME, Novo Nordisk A/S, Måløv, Denmark (R.A.N., D.K.B., C.G.-J., C.S.); Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark (E.J., T.B.S.); Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark (T.B.S.); and Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester, United Kingdom (A.G.)., Galetin A; Development ADME, Novo Nordisk A/S, Måløv, Denmark (R.A.N., D.K.B., C.G.-J., C.S.); Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark (E.J., T.B.S.); Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark (T.B.S.); and Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester, United Kingdom (A.G.)., Säll C; Development ADME, Novo Nordisk A/S, Måløv, Denmark (R.A.N., D.K.B., C.G.-J., C.S.); Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark (E.J., T.B.S.); Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark (T.B.S.); and Centre for Applied Pharmacokinetic Research, School of Health Sciences, The University of Manchester, Manchester, United Kingdom (A.G.) RNQR@novonordisk.com CXLS@novonordisk.com.
Jazyk: angličtina
Zdroj: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Oct 16; Vol. 52 (11), pp. 1170-1180. Date of Electronic Publication: 2024 Oct 16.
DOI: 10.1124/dmd.123.001441
Abstrakt: Drug-drug interaction (DDI) assessment of therapeutic peptides is an evolving area. The industry generally follows DDI guidelines for small molecules, but the translation of data generated with commonly used in vitro systems to in vivo is sparse. In the current study, we investigated the ability of advanced human hepatocyte in vitro systems, namely HepatoPac, spheroids, and Liver-on-a-chip, to assess potential changes in regulation of CYP1A2, CYP2B6, CYP3A4, SLCO1B1, and ABCC2 in the presence of selected therapeutic peptides, proteins, and small molecules. The peptide NN1177, a glucagon and GLP-1 receptor co-agonist, did not suppress mRNA expression or activity of CYP1A2, CYP2B6, and CYP3A4 in HepatoPac, spheroids, or Liver-on-a-chip; these findings were in contrast to the data obtained in sandwich cultured hepatocytes. No effect of NN1177 on SLCO1B1 and ABCC2 mRNA was observed in any of the complex systems. The induction magnitude differed across the systems (e.g., rifampicin induction of CYP3A4 mRNA ranged from 2.8-fold in spheroids to 81.2-fold in Liver-on-a-chip). Small molecules, obeticholic acid and abemaciclib, showed varying responses in HepatoPac, spheroids, and Liver-on-a-chip, indicating a need for EC 50 determinations to fully assess translatability data. HepatoPac, the most extensively investigated in this study (3 donors), showed high potential to investigate DDIs associated with CYP regulation by therapeutic peptides. Spheroids and Liver-on-a-chip were only assessed in one hepatocyte donor and further evaluations are required to confirm their potential. This study establishes an excellent foundation toward the establishment of more clinically-relevant in vitro tools for evaluation of potential DDIs with therapeutic peptides. SIGNIFICANT STATEMENT: At present, there are no guidelines for drug-drug interaction (DDI) assessment of therapeutic peptides. Existing in vitro methods recommended for assessing small molecule DDIs do not appear to translate well for peptide drugs, complicating drug development for these moieties. Here, we establish evidence that complex cellular systems have potential to be used as more clinically-relevant tools for the in vitro DDI evaluation of therapeutic peptides.
(Copyright © 2024 by The Author(s).)
Databáze: MEDLINE
Externí odkaz: